Latest research on Vectibix

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

Latest findings

Cetuximab (Erbitux), trastuzumab (Herceptin), and panitumumab (Vectibix) were purchased from Merck (Whitehouse Station, NJ), Roche (Basel, Switzerland), and Amgen (Thousand Oaks, CA), respectively. [source, 2016]
The search for unpublished RCTs or those in progress was from their metaRegister of Controlled Trials [38] using the following search terms: monoclonal antibodies; mAb; anti-VEGF; anti-EGRF; bevacizumab OR, Avastin OR. panitumumab OR. Vectibix cetuximab OR. Erbitux OR. colorectal neoplasms OR. colorectal cancer OR. colorectal carcinomas. [source, 2015]
In 2004, the EGFR inhibitor cetuximab (Erbitux) was approved in the US for the second-line treatment of mCRC in patients whose tumors overexpress EGFR [6], and in 2006, the EGFR inhibitor panitumumab (Vectibix) was approved for the second-line treatment of mCRC in patients with disease progression on or following conventional chemotherapies [7]. [source, 2015]
Monoclonal antibodies are being successfully used in immunotherapy of diseases such as cancer where they target antigens such as HER2 using trastuzumab (Herceptin), EGFR with panitumumab (Vectibix) and VEGF-A with bevacizumab (Avastin). [source, 2015]
Other fully humanized IgG anti-EGFR antibodies under consideration include zalutumumab (HuMax-EGFr, Genmab, Copenhagen, Denmark) and panitumumab (Vectibix, Amgen; Thousand Oaks, CA, USA), and these are being investigated in phase II and III studies [2,23,37,67,80]. [source, 2015]
In addition, given the rising CEA level and the clinical picture suggestive of systemic tumor progression, the patient was restarted on systemic chemotherapy with irinotecan/panitumumab (Vectibix). [source, 2015]
This postmarketing surveillance study was planned to include all patients treated with panitumumab (Vectibix) from the start date (June 15, 2010) of its launch in Japan (ClinicalTrials.gov: NCT02089737; Japan Pharmaceutical Information Center–Clinical Trials Information: 132374) [10]. [source, 2015]
To promote appropriate use and evaluate safety information, a Vectibix Appropriate Use Committee, a Vectibix Safety Evaluation Committee, and a Vectibix ILD review subcommittee were organized. [source, 2015]
The Vectibix ILD review subcommittee was established to evaluate the relationship between panitumumab and ILD, or the tendency of ILD occurrence, from the viewpoint of a third party on the basis of information on the treatment of patients in whom ILD developed or who had symptoms or disease states related to ILD after they received panitumumab. [source, 2015]
Regarding ILD risk, a letter recommending to avoid administration was sent from the Vectibix Appropriate Use Committee if the patient had a history of ILD or pulmonary fibrosis and previous or concurrent ILD with the FOLFIRI regimen. [source, 2015]